Significantly Reduced the Need for SCS Use or Sino‑Nasal Surgery vs Placebo in a Prespecified Multiplicity-Controlled Pooled Analysis of SINUS‑24 and SINUS‑521,2,a
TIME TO FIRST SCS USE OR CRSwNP SURGERY DURING THE TREATMENT PERIOD
74%Fewer Patients Required
SCS Use at Week 52
SCS Use at Week 52
(HR: 0.26 [95% CI: 0.18, 0.38])1
- 75% REDUCTION IN SCS COURSES PER YEAR
(RR: 0.25 [95% CI: 0.17, 0.37])1
83%Fewer Patients Required
sino-nasal
surgery at week 52
sino-nasal
surgery at week 52
(HR: 0.17 [95% CI: 0.07, 0.46])1
aIndividually, SCS reduction and need for sino-nasal surgery were not multiplicity-adjusted endpoints.3
HR, hazard ratio; RR, risk ratio.
Explore the Safety Data and Study Designs
Dosage and
Administration
Administration
See the recommended dosing and
administration options for patients
on DUPIXENT.